Navigation Links
Bone drug is mixed blessing for breast cancer patients
Date:9/26/2011

A drug used to protect bone may extend survival in older breast cancer patients, according to researchers at the Universities of Sheffield and Leeds.

The AZURE trial, led by Professor Robert Coleman from the University of Sheffield, has revealed that the bisphosphonate drug zoledronic acid boosts disease-free survival in postmenopausal breast cancer patients but may have an adverse effect on younger women.

The full results of the trial were presented today (25 September 2011) at the European Multidisciplinary Cancer Congress in Stockholm and subsequently published in the New England Journal of Medicine.

Bisphosphonate drugs, like zoledronic acid, are used mainly to treat osteoporosis. However, they may also be given to breast cancer patients to protect against the effects of secondary bone cancer.

The trial, which started in 2003, involved 3,360 women with early breast cancer from 174 centres in the UK, Australia, Spain, Ireland, Portugal, Taiwan and Thailand. Patients were randomised to receive standard chemotherapy and/or endocrine therapy (hormone therapy) for their breast cancer, to try and prevent recurrence or spread of the disease, with or without zoledronic acid.

Contrary to previous studies, there was no significant difference in disease-free or overall survival between patients who received zoledronic acid and those that did not, looking at the study population as a whole. However, the addition of zoledronic acid did bring significant benefits to an important subgroup of women within the trial.

The study revealed that women who had completely passed through the menopause (five years since last period) had significantly improved disease-free and overall survival. Here, the overall survival rate at five years was 85 per cent compared to 79 per cent for women who did not receive zoledronic acid. The benefit was independent of the characteristics of the disease as defined by the stage of the tumour, oestrogen receptor status, and lymph node involvement. For all other patients, overall five year survival was similar at 86 per cent in the zoledronic acid group and 85 per cent in the control group.

Most surprisingly, it was the recurrence rates outside bone that were most profoundly affected by the zoledronic acid with clear benefit in the postmenopausal women but a possible adverse effect in younger women. The relative risk for developing metastases outside bone during treatment with zoledronic acid was approximately halved in the postmenopausal women compared with the younger patients (p <.001).

The results shed new light on the role that the bones may play in the progress of the disease. The effects on metastasis and recurrence outside bone suggests that the bone marrow is an important sanctuary for tumour cells which can be activated after sometimes many years of dormancy. With help from bone marrow stem cells, these previously dormant tumour cells may then spread via the blood stream to set up metastases at other sites.

Other studies in postmenopausal women and younger women given treatment to induce a menopause with hormone sensitive breast cancer have also indicated benefit for zoledronic acid in early breast cancer.

The AZURE trial is the first study to evaluate the use of zoledronic acid in a broad range of patients. Further data from other similar trials are anticipated later this year.

Professor Robert Coleman said: "The results have shown that zoledronic acid should not be used routinely for the treatment of early breast cancer. However, for those with low levels of female hormones, due either to natural ageing or specific treatments to induce menopause, the approach appears very promising as more women go on to rid themselves of the disease.

"Our findings could mean a major new treatment approach for the tens of thousands of women in the UK who develop breast cancer. We are now investigating the hormone levels in blood and the biology of the breast tumours in samples donated by the AZURE patients to help us better understand the reasons behind our results."

Helen Marshall, Principal Statistician from the University of Leeds' Clinical Trials Research Unit (CTRU), said: "The statistics of this analysis are complex and the results need to be interpreted with a degree of caution. The size and significance of the difference by menopausal status suggests that this finding is genuine, but we will need to carry out further studies to substantiate this exciting result."


'/>"/>

Contact: Shemina Davis, Media Relations Officer
shemina.davis@sheffield.ac.uk
01-142-225-339
University of Sheffield
Source:Eurekalert

Related medicine news :

1. Extending lifespan has mixed effects on learning and memory
2. U.S. Report on Kids Health Brings Mixed Results
3. Antibiotics a Mixed Bag for Kids Ear Infections: Analysis
4. Elder law expert: Health care reform act a mixed bag for seniors
5. Americas Health a Mixed Bag: Report
6. Models Photos May Spur Mixed Messages About Body Image
7. Trials of Type 1 Diabetes Vaccines Bring Mixed Results
8. Master Zhi Gang Sha Dedicates Soul Healing Blessings for Humanity Service to Chile's Earthquake Victims
9. Supporters and opponents of a special blessing for homosexuals share many values
10. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
11. Low forms of cyclin E reduce breast cancer drugs effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, ... Murthy explains how he was inspired to practice medicine at an early age by ... about more than making diagnoses and prescribing medicine,” he states. “It is about building ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 02, 2016 , ... ... high school and while 84 percent of parents report speaking with their child about ... pornography and sexually transmitted diseases. , Mediaplanet is proud to announce the launch of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, ... and the first company to offer robotic imaging to veterinary medicine is sponsoring ... # 941 for the American Association of Equine Practitioners 62nd Annual Convention from ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is a ... versatile lower third titles with just a few clicks of the mouse," said Christina ... 30 lower third animations. Choose from various styles with accented animations, rigid boxes, simplistic ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: ... of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon ... of Water, Global Climate Change and Your Health radio program syndicated on Voice ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... Dec. 2, 2016 Boston Scientific Corporation (NYSE: ... to acquire certain manufacturing assets and capabilities of the ... advanced biological tissue business, as well as a 15% ... million in cash. The Neovasc advanced biological tissue business ... Boston Scientific Lotus™ Valve System. * Upon completion ...
(Date:12/2/2016)... Lianluo Smart Limited (Nasdaq: ... develops, markets and sells medical devices and wearable ... and international markets, recently attended the 2016 ... Progress Forum, co-hosted by the Institute of Interventional ... Guangdong Provincial People,s Hospital and Cardiology Department of ...
Breaking Medicine Technology: